Correlation Between Mineralys Therapeutics, and ProMIS Neurosciences
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and ProMIS Neurosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and ProMIS Neurosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and ProMIS Neurosciences, you can compare the effects of market volatilities on Mineralys Therapeutics, and ProMIS Neurosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of ProMIS Neurosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and ProMIS Neurosciences.
Diversification Opportunities for Mineralys Therapeutics, and ProMIS Neurosciences
-0.67 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Mineralys and ProMIS is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and ProMIS Neurosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ProMIS Neurosciences and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with ProMIS Neurosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ProMIS Neurosciences has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and ProMIS Neurosciences go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and ProMIS Neurosciences
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.64 times more return on investment than ProMIS Neurosciences. However, Mineralys Therapeutics, Common is 1.57 times less risky than ProMIS Neurosciences. It trades about 0.06 of its potential returns per unit of risk. ProMIS Neurosciences is currently generating about 0.0 per unit of risk. If you would invest 807.00 in Mineralys Therapeutics, Common on August 25, 2024 and sell it today you would earn a total of 442.00 from holding Mineralys Therapeutics, Common or generate 54.77% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. ProMIS Neurosciences
Performance |
| Timeline |
| Mineralys Therapeutics, |
| ProMIS Neurosciences |
Mineralys Therapeutics, and ProMIS Neurosciences Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and ProMIS Neurosciences
The main advantage of trading using opposite Mineralys Therapeutics, and ProMIS Neurosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, ProMIS Neurosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will offset losses from the drop in ProMIS Neurosciences' long position.| Mineralys Therapeutics, vs. Eliem Therapeutics | Mineralys Therapeutics, vs. HCW Biologics | Mineralys Therapeutics, vs. RenovoRx | Mineralys Therapeutics, vs. Tempest Therapeutics |
| ProMIS Neurosciences vs. biOasis Technologies | ProMIS Neurosciences vs. Zenith Capital Corp | ProMIS Neurosciences vs. Hemogenyx Pharmaceuticals Plc | ProMIS Neurosciences vs. Fennec Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |